tiprankstipranks
Aclaris Therapeutics reports Q4 EPS (2c), consensus (34c)
PremiumThe FlyAclaris Therapeutics reports Q4 EPS (2c), consensus (34c)
3M ago
Aclaris Therapeutics Executive Team Undergoes Major Changes
PremiumCompany Announcements
Aclaris Therapeutics Executive Team Undergoes Major Changes
3M ago
Aclaris Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Aclaris Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
4M ago
Aclaris downgraded to Hold at Jefferies after ATI-1777 data reported
PremiumThe FlyAclaris downgraded to Hold at Jefferies after ATI-1777 data reported
4M ago
Aclaris Therapeutics downgraded to Hold from Buy at Jefferies
PremiumThe Fly
Aclaris Therapeutics downgraded to Hold from Buy at Jefferies
4M ago
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
PremiumPress Releases
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
4M ago
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
PremiumPress ReleasesAclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
5M ago
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
6M ago
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100